News

Inverna Therapeutics will attend BioFIT 2026 in Marseille. CEO Poul Sørensen speaks on alternative financing through patient association partnerships.

Read more

Meet Inverna Therapeutics at TIDES Europe 2026, November 3–5 in Amsterdam — Europe’s leading event for oligonucleotides, peptides, mRNA and drug delivery.

Read more

Inverna Therapeutics will present its portfolio and scientific progress at NLSDays, October 8–9, 2026 in Stockholm. Meet our CEO for partnering opportunities.

Read more

Inverna Therapeutics is taking part in the 26th Biotech in Europe Forum, on 7–8 October 2026 in Basel, to present its RNA therapy platform.

Read more

Inverna Therapeutics is pleased to announce its participation in the Oligonucleotides for CNS Summit Europe 2026, held April 21 – 23, 2026 in Amsterdam, Netherlands.

Read more

Inverna Therapeutics is pleased to announce its participation in the Life Science Spring Innovation Week 2026, featuring BIO-Europe Spring 2026, held March 23 – 25, 2026, and the directly following LSX World Congress Europe 2026, March 25 – 26, 2026.

Read more

Inverna Therapeutics is pleased to announce that Chief Executive Officer, Poul Sørensen, has been invited to present at the RNA Leaders Europe 2026 Congress, taking place from March 17 to 19, 2026, at the Austria Center in Vienna.

Read more

Inverna Therapeutics is pleased to announce that CEO Poul Sørensen will be presenting at the upcoming BioCapital 2026 conference organized by EQT Life Sciences.

Read more

The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.

Read more

The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.

Read more